Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Elixxer

DB:2LQA
Snowflake Description

Imperfect balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2LQA
DB
CA$20M
Market Cap
  1. Home
  2. DE
  3. Diversified Financials
Company description

Elixxer Ltd., an investment holding company, holds investments in private cannabis operations in Canada, Australia, Italy, Jamaica, and Switzerland. The last earnings update was 121 days ago. More info.


Add to Portfolio Compare Print
  • Elixxer has significant price volatility in the past 3 months.
2LQA Share Price and Events
7 Day Returns
-6.5%
DB:2LQA
12.3%
DE Capital Markets
7.2%
DE Market
1 Year Returns
-
DB:2LQA
-8.8%
DE Capital Markets
-17.5%
DE Market
2LQA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Elixxer (2LQA) -6.5% -25.6% - - - -
DE Capital Markets 12.3% -26.5% -16.8% -8.8% -29% -56.3%
DE Market 7.2% -22.3% -26.1% -17.5% -25.7% -29.1%
1 Year Return vs Industry and Market
  • No trading data on 2LQA.
  • No trading data on 2LQA.
Price Volatility
2LQA
Industry
5yr Volatility vs Market

2LQA Value

 Is Elixxer undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Elixxer. This is due to cash flow or dividend data being unavailable. The share price is €0.0145.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Elixxer's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Elixxer's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2LQA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in CAD CA$-0.03
TSXV:ELXR Share Price ** TSXV (2020-03-27) in CAD CA$0.04
Germany Capital Markets Industry PE Ratio Median Figure of 17 Publicly-Listed Capital Markets Companies 21.49x
Germany Market PE Ratio Median Figure of 400 Publicly-Listed Companies 16.49x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Elixxer.

DB:2LQA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:ELXR Share Price ÷ EPS (both in CAD)

= 0.04 ÷ -0.03

-1.21x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Elixxer is loss making, we can't compare its value to the DE Capital Markets industry average.
  • Elixxer is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Elixxer's expected growth come at a high price?
Raw Data
DB:2LQA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.21x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Germany Capital Markets Industry PEG Ratio Median Figure of 7 Publicly-Listed Capital Markets Companies 1.49x
Germany Market PEG Ratio Median Figure of 252 Publicly-Listed Companies 1.22x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Elixxer, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Elixxer's assets?
Raw Data
DB:2LQA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in CAD CA$0.04
TSXV:ELXR Share Price * TSXV (2020-03-27) in CAD CA$0.04
Germany Capital Markets Industry PB Ratio Median Figure of 32 Publicly-Listed Capital Markets Companies 1.61x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.42x
DB:2LQA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:ELXR Share Price ÷ Book Value per Share (both in CAD)

= 0.04 ÷ 0.04

0.88x

* Primary Listing of Elixxer.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Elixxer is good value based on assets compared to the DE Capital Markets industry average.
X
Value checks
We assess Elixxer's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Capital Markets industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Capital Markets industry average (and greater than 0)? (1 check)
  5. Elixxer has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

2LQA Future Performance

 How is Elixxer expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Elixxer has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
41.2%
Expected Capital Markets industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Elixxer expected to grow at an attractive rate?
  • Unable to compare Elixxer's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Elixxer's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Elixxer's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:2LQA Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Capital Markets Industry Earnings Growth Rate Market Cap Weighted Average 41.2%
Germany Capital Markets Industry Revenue Growth Rate Market Cap Weighted Average 1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2LQA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2LQA Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:2LQA Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-09-30 -6 -13
2019-06-30 0 -6 -11
2019-03-31 0 -6 -16
2018-12-31 0 -5 -14
2018-09-30 0 -5 -17
2018-06-30 0 -5 -19
2018-03-31 0 -4 -9
2017-12-31 -3 -9
2017-09-30 -3 -5
2017-06-30 -3 -5
2017-03-31 -3 -6
2016-12-31 -3 -6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Elixxer is high growth as no earnings estimate data is available.
  • Unable to determine if Elixxer is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2LQA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Elixxer Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2LQA Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:2LQA Past Financials Data
Date (Data in CAD Millions) EPS *
2019-09-30 -0.03
2019-06-30 -0.03
2019-03-31 -0.04
2018-12-31 -0.04
2018-09-30 -0.05
2018-06-30 -0.06
2018-03-31 -0.03
2017-12-31 -0.04
2017-09-30 -0.02
2017-06-30 -0.02
2017-03-31 -0.02
2016-12-31 -0.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Elixxer will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of 2LQA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Elixxer's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Diversified Financials companies here
  3. Elixxer's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Elixxer's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Elixxer has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

2LQA Past Performance

  How has Elixxer performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Elixxer's growth in the last year to its industry (Capital Markets).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Elixxer does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Elixxer's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Elixxer's 1-year growth to the DE Capital Markets industry average as it is not currently profitable.
Earnings and Revenue History
Elixxer's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Elixxer Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2LQA Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 -13.10 8.30
2019-06-30 -0.02 -11.31 4.41
2019-03-31 -0.09 -16.09 11.18
2018-12-31 0.20 -13.97 10.64
2018-09-30 0.17 -16.53 13.52
2018-06-30 0.29 -18.55 16.90
2018-03-31 0.26 -9.17 7.72
2017-12-31 -9.00 6.96
2017-09-30 -5.05 2.94
2017-06-30 -4.88 2.34
2017-03-31 -5.60 2.60
2016-12-31 -5.75 2.70
2016-09-30 -7.86 4.03
2015-09-30 -0.17 0.15

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Elixxer has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Elixxer has efficiently used its assets last year compared to the DE Capital Markets industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Elixxer improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Elixxer's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Capital Markets industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Elixxer has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

2LQA Health

 How is Elixxer's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Elixxer's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Elixxer's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Elixxer has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Elixxer's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Elixxer Company Filings, last reported 5 months ago.

DB:2LQA Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 20.88 5.14 0.32
2019-06-30 23.72 2.51 3.47
2019-03-31 17.40 4.32 1.25
2018-12-31 19.93 3.03 2.92
2018-09-30 17.67 2.53 6.57
2018-06-30 18.39 2.49 11.10
2018-03-31 19.67 2.12 16.45
2017-12-31 5.76 0.00 5.98
2017-09-30 1.58 0.33 2.70
2017-06-30 4.00 0.42 4.33
2017-03-31 5.40 0.33 5.53
2016-12-31 4.95 0.00 4.83
2016-09-30 7.55 0.00 7.26
2015-09-30 8.29 0.00 8.17
  • Elixxer's level of debt (24.6%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Elixxer's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Elixxer has less than a year of cash runway based on current free cash flow.
  • Elixxer has less than a year of cash runway if free cash flow continues to grow at historical rates of 34.6% each year.
X
Financial health checks
We assess Elixxer's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Elixxer has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

2LQA Dividends

 What is Elixxer's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Elixxer dividends.
If you bought €2,000 of Elixxer shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Elixxer's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Elixxer's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2LQA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Germany Capital Markets Industry Average Dividend Yield Market Cap Weighted Average of 15 Stocks 3.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 320 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2LQA Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Elixxer has not reported any payouts.
  • Unable to verify if Elixxer's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Elixxer's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Elixxer has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Elixxer's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Elixxer afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Elixxer has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

2LQA Management

 What is the CEO of Elixxer's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mazen Haddad
COMPENSATION CA$463,943
AGE 45
TENURE AS CEO 0.9 years
CEO Bio

Mr. Mazen Haddad serves as the Chief Information Officer of Legal Research Center, Inc. Mr. Haddad served as an Interim Chief Executive Officer of Argex Titanium Inc. from December 18, 2015 to July 2016 and served as its Interim President since December 18, 2015. He served as the Chairman, Chief Executive Officer and President of Knowlton Capital Inc. (formerly, Buzz Telecommunications Services Inc.) since August 30, 2013. He served as Vice President at SGI Capital Corp. since April 2002. He served as the President of Township Capital Inc. from 2005 to 2010. He served as a consultant for Palos Capital Pool, L.P., from 2006 to 2010. He served as Secretary of Cowansville Capital, Inc. From September 2000 to January 2002, he served as the Chief Operating Officer at Globeam Corp. From 1997 to September 2000, Mr. Haddad served as Director of Product Marketing & Internetworking Systems at CTI Datacom Inc. and served as its Manager of Special Projects from 1995 to 1997. He served as Advisor of Gale Force Petroleum Inc. (formerly, Rolland Energy Inc.) since May 2011. He has been Co-Chairman of LGC Capital Ltd. July 12, 2016. He has been Chief Executive Officer of LGC Capital Ltd. since April 3, 2019 and its Director since 2008. He served as Co-Chairman of LGC Capital Ltd. July 12, 2016. He has been an Independent Director of BlueTree Wireless Data Inc. since 2003. He has been a Director of Level Vision Electronics Ltd. since January 6, 2009. He served as the Chairman of SGI Properties Canada Fund LP. He served as the Chairman of Argex Titanium Inc. from June 23, 2015 to July 2016. He has been a Director of Argex Titanium Inc. since June 20, 2011. He served as a Director of Goldbard Capital Corporation from June 11, 2007 to July 2010. He served as a Director of Gale Force Petroleum Inc. from January 28, 2008 to May 2011. He served as a Director of Huntingdon Capital Inc. since 2004. He served as a Director of Cowansville Capital, Inc., since April 20, 2004 and Knowlton Capital Inc., since 2008. He served as a Director of Oyster Oil and Gas Ltd. (formerly, MetroBridge Networks International Inc.) since 2004. He served as a Director of Argex Silver Capital Inc. Mr. Haddad holds a Bachelor of Arts in Economics from Emory University of Atlanta, Georgia, a Certificate in International Trade from the Southern Center in Atlanta, Georgia and a Certificate in IP Routing Essentials from LM Ericsson Telephone Co. He holds a degree in Electrical Engineering from the University of Maryland.

CEO Compensation
  • Mazen's compensation has increased whilst company is loss making.
  • Mazen's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Elixxer management team in years:

1.2
Average Tenure
51
Average Age
  • The average tenure for the Elixxer management team is less than 2 years, this suggests a new team.
Management Team

Mazen Haddad

TITLE
CEO & Director
COMPENSATION
CA$464K
AGE
45
TENURE
0.9 yrs

John A. McMullen

TITLE
President
COMPENSATION
CA$128K
TENURE
3 yrs

Ferras Zalt

TITLE
Executive Chairman
AGE
56
TENURE
0.3 yrs

Mark Shinners

TITLE
Chief Financial Officer
AGE
41
TENURE
0.9 yrs

Remy Di Meglio

TITLE
Chief Operating Officer
TENURE
1.4 yrs

Guy Charette

TITLE
Legal Council
AGE
65

Jeanne van Wyk

TITLE
Vice President of Communications

Daniel Lubienietzky

TITLE
VP of Corporate Development
TENURE
1.6 yrs

Richard Widmann

TITLE
EVP of Commercial
AGE
51
TENURE
0.9 yrs

Kym No

TITLE
Corporate Controller
TENURE
1.7 yrs
Board of Directors Tenure

Average tenure and age of the Elixxer board of directors in years:

5
Average Tenure
52.5
Average Age
  • The tenure for the Elixxer board of directors is about average.
Board of Directors

Mazen Haddad

TITLE
CEO & Director
COMPENSATION
CA$464K
AGE
45
TENURE
12.2 yrs

Ferras Zalt

TITLE
Executive Chairman
AGE
56
TENURE
0.8 yrs

Mohammed Ghafari

TITLE
Independent Director
COMPENSATION
CA$30K
TENURE
3.3 yrs

Dave Lenigas

TITLE
Director
COMPENSATION
CA$154K
AGE
58
TENURE
5 yrs

Rafi Hazan

TITLE
Director
COMPENSATION
CA$48K
AGE
49
TENURE
14.2 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Elixxer individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
25. Mar 20 Buy Ferras Zalt Individual 24. Mar 20 24. Mar 20 500,000 €0.02 €11,468
18. Mar 20 Buy Ferras Zalt Individual 17. Mar 20 17. Mar 20 22,297 €0.02 €508
10. Feb 20 Buy Ferras Zalt Individual 06. Feb 20 06. Feb 20 2,000,000 €0.03 €54,808
20. Sep 19 Buy Ferras Zalt Individual 19. Sep 19 19. Sep 19 300,000 €0.06 €17,575
30. Jan 20 Buy Ferras Zalt Individual 29. Jan 20 29. Jan 20 825,000 €0.03 €22,717
23. Dec 19 Buy Ferras Zalt Individual 18. Dec 19 18. Dec 19 400,000 €0.03 €12,480
10. Dec 19 Buy Ferras Zalt Individual 09. Dec 19 09. Dec 19 264,000 €0.03 €7,210
06. Dec 19 Buy Ferras Zalt Individual 05. Dec 19 05. Dec 19 300,000 €0.03 €8,200
04. Dec 19 Buy Ferras Zalt Individual 03. Dec 19 03. Dec 19 200,000 €0.02 €4,879
18. Nov 19 Buy Ferras Zalt Individual 14. Nov 19 15. Nov 19 880,000 €0.04 €35,538
23. Oct 19 Buy Ferras Zalt Individual 22. Oct 19 22. Oct 19 100,000 €0.05 €4,837
18. Oct 19 Buy Ferras Zalt Individual 17. Oct 19 17. Oct 19 250,000 €0.05 €12,565
11. Oct 19 Buy Ferras Zalt Individual 10. Oct 19 10. Oct 19 400,000 €0.05 €20,716
23. Sep 19 Buy Ferras Zalt Individual 20. Sep 19 20. Sep 19 200,000 €0.06 €12,416
19. Sep 19 Buy Ferras Zalt Individual 18. Sep 19 18. Sep 19 40,000 €0.06 €2,201
29. Jul 19 Buy John A. McMullen Individual 26. Jul 19 26. Jul 19 100,000 €0.06 €5,541
17. Jul 19 Buy Ferras Zalt Individual 16. Jul 19 16. Jul 19 200,000 €0.07 €13,595
15. Jul 19 Buy Ferras Zalt Individual 12. Jul 19 15. Jul 19 1,000,000 €0.06 €59,951
05. Jun 19 Buy Remy Di Meglio Individual 04. Jun 19 04. Jun 19 480,000 €0.07 €31,812
04. Jun 19 Buy Arlington Management Employees, LLC Company 31. May 19 31. May 19 24,000,000 €0.07 €1,592,905
31. May 19 Buy Remy Di Meglio Individual 29. May 19 29. May 19 440,000 €0.07 €29,217
02. May 19 Buy Arlington Management Employees, LLC Company 01. May 19 01. May 19 80,000,000 €0.07 €5,304,425
X
Management checks
We assess Elixxer's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Elixxer has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

2LQA News

Simply Wall St News

2LQA Company Info

Description

Elixxer Ltd., an investment holding company, holds investments in private cannabis operations in Canada, Australia, Italy, Jamaica, and Switzerland. The company was formerly known as LGC Capital Ltd. and changed its name to Elixxer Ltd. in August 2019. Elixxer Ltd. is based in Montreal, Canada.

Details
Name: Elixxer Ltd.
2LQA
Exchange: DB
Founded:
CA$12,571,873
560,508,032
Website: http://www.elixxer.com
Address: Elixxer Ltd.
800 Place Victoria,
Suite 3700,
Montreal,
Quebec, H4Z 1E9,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV ELXR Common Shares TSX Venture Exchange CA CAD 13. Jul 2016
OTCPK ELIX.F Common Shares Pink Sheets LLC US USD 13. Jul 2016
DB 2LQA Common Shares Deutsche Boerse AG DE EUR 13. Jul 2016
TSXV QBA COM TSX Venture Exchange CA CAD 29. Mar 2020
Number of employees
Current staff
Staff numbers
0
Elixxer employees.
Industry
Asset Management and Custody Banks
Diversified Financials
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/29 00:13
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2019/11/29
Last earnings filing: 2019/11/29
Last earnings reported: 2019/09/30
Last annual earnings reported: 2019/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.